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RMRP was the first non-coding nuclear RNA gene implicated in a disease. Its mutations cause 
cartilage-hair hypoplasia (CHH), an autosomal recessive skeletal dysplasia with growth failure, 
immunodeficiency, and a high risk for malignancies. This study aimed to gain further insight into 
the role of RNA Component of Mitochondrial RNA Processing Endoribonuclease (RMRP) in cellular 
physiology and disease pathogenesis. We combined transcriptome analysis with single-cell analysis 
using fibroblasts from CHH patients and healthy controls. To directly assess cell cycle progression, 
we followed CHH fibroblasts by pulse-labeling and time-lapse microscopy. Transcriptome analysis 
identified 35 significantly upregulated and 130 downregulated genes in CHH fibroblasts. The 
downregulated genes were significantly connected to the cell cycle. Multiple other pathways, involving 
regulation of apoptosis, bone and cartilage formation, and lymphocyte function, were also affected, as 
well as PI3K-Akt signaling. Cell-cycle studies indicated that the CHH cells were delayed specifically in the 
passage from G2 phase to mitosis. Our findings expand the mechanistic understanding of CHH, indicate 
possible pathways for therapeutic intervention and add to the limited understanding of the functions of 
RMRP.
Cartilage hair-hypoplasia (CHH, MIM #250250) is a rare autosomal recessive disorder characterized by meta-
physeal chondrodysplasia leading to short stature (adult height on average 110–135 cm), hair hypoplasia, variable 
immunodeficiency, anemia, increased risk of malignancies, and Hirschsprung disease1. CHH is caused by muta-
tions in RMRP, a gene that encodes a non-coding RNA, the RNA Component of Mitochondrial RNA Processing 
Endoribonuclease (RMRP)2. The founder mutation n.71 A > G (NCBI reference sequence: NR_003051.3) has been 
detected in almost all previously reported Finnish patients with CHH either in homozygous or heterozygous state3. 
This substitution affects evolutionary conserved nucleotides4, but the direct effect of this variant on the function of 
RMRP remains undescribed, and the variability of phenotype in patients with identical mutations is unexplained1.
Studies in yeast have shown that RMRP participates in mitochondrial DNA replication, rRNA processing and 
cell cycle progression at the end of mitosis5. Functional studies in humans have highlighted the role of RMRP in 
ribosomal assembly and cyclin A2 and B2-dependent cell cycle regulation6. Knockdown of RMRP in a normal 
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human gastric mucosa epithelial cell line and gastric cancer cell lines resulted in cyclin D2 downregulation7. 
CRISPR disruption of RMRP in HeLa cells led to severe defects in cell proliferation and rRNA processing8.
Despite this work the specific pathogenesis of CHH remains incompletely understood. A generalized defect 
in cell proliferation has been speculated to explain several of the clinical manifestations, including disorganized 
growth-plate chondrocyte maturation, hair hypoplasia, immunodeficiency and impaired spermatogenesis1,9,10. 
Defective cell proliferation has been confirmed in T and B lymphocytes9,11, erythrocyte progenitors12 and fibro-
blasts9. Other studies have demonstrated increased apoptosis13 in CHH T lymphocytes, as well as a prolonged cell 
cycle with fewer cells entering S phase and a higher proportion of cells remaining in the G2/M phase14.
Most data on the function of RMRP and pathogenesis of CHH are inferred from experimental systems involv-
ing cancer cells and nonhuman cells. As many of the previous observations point toward a direct role of RMRP in 
ribosomal RNA processing and thus potentially transcriptome balance5,6,8, we assessed fibroblast transcriptomes 
in CHH patient cells and healthy control cells and followed up on suggested pathway effects by relevant func-
tional assays. Our transcriptome data support a central role for RMRP in cell cycle regulation, mutations leading 
to slowing down of the process in CHH patients, supported by data from cell-cycle analysis in CHH fibroblasts. 
Other cellular systems relevant for the CHH phenotype were also affected.
Results
Five adults with CHH, all homozygous for the previously described g.70 A > G RMRP mutation2, donated a skin 
biopsy for fibroblast cultures. All had typical phenotypic manifestations of CHH (see Supplementary Table S1, 
Fig. 1A). Five age- and sex-matched healthy adults volunteered for skin biopsies as controls.
Cell growth is abnormal in CHH fibroblasts. Despite identical procedures when culturing fibroblasts 
from skin biopsies, we observed clear differences in cell growth between cases and controls. In primary cultures of 
skin biopsies, the CHH subjects’ cells required a median of 33 days to progress from passage 1 to passage 4, while 
the control fibroblasts required a median of 23 days. This difference in growth rate persisted when frozen fibro-
blasts were recultured (see Supplementary Fig. S1). After culturing an equal number of fibroblasts and measuring 
cell counts daily for the following three days, the cases’ cell numbers were lower already at day 1 as compared to 
control cells (see Supplementary Fig. S1). The number of case fibroblasts in daily measurements was 67–21% of 
the control cell counts throughout the culture period.
RNA sequencing reveals 35 Up- and 130 downregulated genes in CHH fibroblasts. The quality of 
RNA samples, extracted from passage 2–5 fibroblasts from 5 CHH cases (in total 20 samples) and 5 matched con-
trols (19 samples), was high and similar in case and control samples (see Supplementary Table S2). 10 ng of total 
RNA from each sample was analyzed by the modified single-cell tagged reverse transcription (STRT) sequencing 
method targeting 5′ ends of transcripts and transcription start sites15,16. Four samples (two case passages and two 
control passages) were excluded due to low 5′ capture rate, indicative of partial RNA degradation, leaving 18 and 
17 acceptable samples for analysis, respectively (see Supplementary Table S3). The qualified samples averaged 
3.17 million unique sequence reads per sample; of these 2.84 million were successfully mapped to the reference 
genome (hg19), and 1.99 million of these mapped to the 5′ coding part of known genes. These numbers did not 
differ between the case and control groups of samples (see Supplementary Table S3). The sequencing data have 
been deposited at the European Nucleotide Archive (https://www.ebi.ac.uk/ena) under the accession number 
PRJEB23608.
The passage of cells did not have a major effect on the transcriptome as shown by hierarchical clustering 
(see Fig. 1B) and principal component analysis (see Supplementary Fig. S2) of the case and control samples. 
Comparing cases and controls irrespective of passage, there were 35 genes that were significantly upregulated, and 
130 genes significantly downregulated in CHH fibroblasts (see Supplementary Table S4).
Quantitative real-time reverse transcriptase PCR (qRT-PCR) validation of CDK2, IFITM1, CDKN1A and 
BCL2L1 gene expression was in line with the results of the STRT RNA-seq data (see Supplementary Fig. S3). 
The expression of CDK2 (by the independent samples t-test p-value 0.0087), IFITM1 (p-value 0.0203), CDKN1 
(p-value 0.0113) and BCL2L1 (p-value 0.0255) differed significantly between the CHH patients and controls. 
Significantly between the CHH patients and controls.
Downregulated genes are connected to the cell cycle pathways. The genes that were downregu-
lated in CHH cases compared to controls were significantly connected to the cell cycle (p-value < 5.1E-4) (see 
Fig. 1C). The downregulated Gene Ontology (GO) Biological processes categories involving chromosome organ-
ization, mitotic cell cycle, and cell cycle were strongly enriched in this group of genes. Correspondingly, the GO 
Cellular component and molecular function categories involving chromosomes and DNA packaging and binding 
were also enriched in the downregulated genes. Looking at enriched Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathways in the downregulated genes (see Fig. 1D, Supplementary Table S5A), one finds a corresponding 
enrichment of DNA replication and cell cycle pathways17–19.
Upregulated genes involve PI3K-Akt signaling pathway. The GO Biological process “Regulation of 
molecular function” was enriched in the genes that were upregulated in CHH case fibroblasts as compared with 
controls, and Cellular Component GO categories involving e.g., extracellular exosomes, vesicles and organelles 
were significantly enriched in these cells. Furthermore, a set of genes involved in the Molecular function GO cat-
egory enzyme activator activity was enriched in the CHH case fibroblasts. Finally, the KEGG pathway involving 
PI3K-Akt signaling was significantly upregulated (p-value < 2.2E-3) in the CHH case cells (see Supplementary 
Fig. S4, Supplementary Table S5B).
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Figure 1. Transcriptome analysis of fibroblasts from CHH cases and healthy controls. (A) Male individual 
with CHH with disproportionate short stature and hair hypoplasia. (B) Heatmap showing genes that are 
significantly differentially expressed between fibroblasts from CHH cases and healthy controls as well as 
hierarchical clustering of the samples based on the expression of all these genes. Higher expression is marked 
in orange/red, lower in blue. The gene names (on the left) together with sample codes (above each column) can 
be visualized in the high-resolution image. An identical list of the genes included in the heatmap, in identical 
order, together with additional information is available also as Supplementary Table S4. Numbering of patient 
samples is identical to the numbering in Supplementary Table S1. Cases/controls and passages 1/2/3/4/5 are 
color-coded. For each of the five cases and five controls, we analyzed 2–4 samples from different passages. (C) 
Pie chart showing the 25 most enriched Gene Ontology, Biological processes terms (GO_BP categories) in 
CHH fibroblasts, based on genes that are significantly downregulated in the STRT analysis. Numbers depict 
the number of genes involved in each category. (D) KEGG Pathway analysis of the genes that are significantly 
downregulated in CHH fibroblasts (marked in red). Images were obtained by KEGG, Kanehisa Laboratories.
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CHH fibroblasts demonstrate prolonged cell cycle due to the delay in progression from G2 to G1. 
To directly assess cell cycle progression, we followed CHH fibroblasts by pulse-labeling and time-lapse micros-
copy. The absolute majority of both CHH and control cells remained viable, as 5 out of 800 control cells and 2 out 
of 800 CHH cells died when monitored by time-lapse microscopy for 29 h. Further, no difference in the number 
of dead cells was detected by visual inspection during cell culturing. This indicates that reduced accumulation of 
CHH case cells was not due to excessive cell death. Similarly, we found no difference in the proportion of CHH 
and control cells that incorporated EdU during a 30 h exposure, suggesting that reduced proliferation of CHH 
cells was due to a prolonged cell cycle rather than to cell cycle exit (see Supplementary Fig. S5). We therefore 
pulse-labeled S-phase cells with EdU and followed the DNA content of labeled cells using high content micros-
copy (see Fig. 2A). Five hours after an EdU pulse, the majority of both control and CHH cells had reached 4N 
DNA content, indicating that S-phase duration was similar between the cell types (see Fig. 2B). During the sub-
sequent five hours, cells started passing mitosis, as evidenced by the rise of an EdU-positive population with 2N 
DNA content. Interestingly, we found that 10 h after an EdU pulse, CHH cells showed a higher proportion of 4N 
DNA content compared to control cells (see Figs 2B,C and S6), indicating that CHH cells were delayed in the 
progression from G2 to G1.
The duration of mitosis is normal in CHH Fibroblasts. To assess if the delay occurred in G2-phase or in 
mitosis, we measured the duration of mitosis by time-lapse microscopy. In both cell types, more than 90% of cells 
completed mitosis within 30 min. Although we cannot exclude that CHH cells showed a minor delay in mitosis, 
only 3% of cells required more than 40 minutes to complete mitosis (see Fig. 2D). This suggested that the cell cycle 
delay observed in Fig. 2C was not due to a mitotic delay, but rather that CHH cells were delayed specifically in the 
passage from G2 phase to mitosis.
Figure 2. CHH fibroblasts are delayed in G2 phase. (A) Schematic presentation of the setup used in B and 
C. Fibroblasts were pulse-labeled with EdU and samples were harvested at the indicated time points. (B) 
CHH fibroblasts are delayed in transition from G2 to G1. The indicated cell lines were followed as outlined 
in A. Each circle corresponds to one fibroblast. (C) CHH fibroblasts are delayed in transition from G2 to 
G1. Quantification of fibroblasts denoted in rectangle in B, showing percentage of 4 N cells of EdU positive 
population 10 h after EdU pulse. Students t-test. Error bars show s.e.m. (D) The graph shows quantification of 
mitotic duration for the indicated cell lines. There was no major mitotic delay in CHH fibroblasts.
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Discussion
We demonstrated slow cell growth, defective cell cycle progression, and transcriptome differences in fibroblasts 
from patients with CHH compared to healthy controls. Impaired growth of cultured CHH fibroblasts was con-
sistent with previous reports9 and was observed in primary fibroblast cultures from skin biopsies, as well as after 
reculturing of frozen cells.
The CHH gene was originally positionally cloned as the first disease-causing lncRNA gene2. The causative 
role of the Finnish mutation has been established by genetic studies earlier20–22, and therefore the study of the 
functional effects of RMRP was based on samples from patients carrying the Finnish founder mutation. As the 
causative mutation is non-coding and regulatory, and all overexpression models likely very unphysiological, we 
did not attempt such experiments to replenish the fibroblasts with an external RMRP gene construct.
Our findings are in good agreement with the clinical manifestations of CHH. When looking at individual up- 
and downregulated genes, more than half could be assigned to cellular functions that are likely to be important 
for clinical manifestations of CHH (see Supplementary Table S6). Only two genes overlapped with previously 
reported up- or downregulated genes in CHH23. This discrepancy is likely due to the use of different cell types 
(peripheral blood lymphocytes vs. fibroblasts) and different methodology, possibly with higher sensitivity of our 
assays.
We performed whole-transcriptome analysis of fibroblasts from both CHH cases and controls and found 
approximately three times more significantly downregulated than upregulated genes in CHH cases. The results 
were independent of the passage, suggesting that the difference was not influenced by progressive defects caused 
by cell culture conditions. Further analysis of GO category and KEGG pathway enrichment within downregulated 
genes revealed a clear signature of perturbations in several components of the cell cycle and cell cycle progression, 
consistent with earlier studies23. Although we did not perform a rescue experiment with wild-type RMRP, we 
used RMRP-mutation negative fibroblasts as control cells.
Our novel finding of the possibly impaired PI3K-Akt signaling in CHH fibroblasts deserves further studies. 
Enrichment of the KEGG pathway involving PI3K-Akt signaling within the upregulated genes in case cells is in agree-
ment with the CHH phenotype, as the pathway has been shown to be involved in growth plate chondrocyte differen-
tiation and regulation of endochondral bone growth in mice24. The pathway also plays a role in several malignancies, 
including lymphomas25, and may contribute to the high risk of non-Hodgkin lymphomas in patients with CHH26. 
These observations may have therapeutic implications and should be explored in future studies. All these findings led 
us to study in more detail which specific components of the cell cycle mechanism were defective in CHH.
To further validate the biological effects of the transcriptome profile changes and to gain further insight 
into slower cell growth in patient fibroblasts, we opted for direct observation of cell cycle effects. We applied 
pulse-labelling and live cell recordings to assess cell cycle progress in single cells. The results showed unequivo-
cally that cell death or exiting from cell cycle did not account for the overall slowed proliferation effects in CHH 
fibroblasts. Furthermore, the S phase progressed at an identical pace in both case and control fibroblasts. Instead, 
case cells accumulated at the G2 phase, suggesting a defect in progression to mitosis, which took a similar time 
for both case and control cells to complete.
Taken together, our findings from fibroblast gene expression patterns and cell cycle measurements on single 
fibroblasts, consistently indicate that RMRP mutations in CHH patients interfere with the cell cycle through 
multiple target genes. Our results strongly support the hypothesis that RMRP as a lncRNA has pleiotropic effects 
on a major part of the cell cycle network rather than acting predominantly through a few target genes. This 
fits well with the broad and even changes on multiple targets in the transcriptomic assay. However, the broad 
changes through the cell cycle are orchestrated by a limited set of actors, most notably Cyclin-dependent kinases 
(CDKs). CDK2 drives progression through S-phase and helps activating CDK1 at the S/G2 border, which results 
in build-up of CDK1 activity that eventually triggers mitotic entry (see Fig. 3)27,28. We noted that in addition to 
regulators of CDK1 target phosphorylation such as CDC25C and MAST-L, CDK2 mRNA levels are lower in 
CHH patient cells, whereas mRNA for the potent CDK inhibitor CDKN1A is upregulated. Our observation of a 
G2 delay in CHH cells is thus consistent with reduced activity and levels of the main players promoting progres-
sion through G2 phase (see Fig. 3).
The functions of lncRNAs are for the most part unknown. Broad regulatory effects on cell cycle have been 
documented on some lncRNAs, such as for LINC00152 regulating progression through mitosis29 and for GAS5 
regulating G0/G1 arrest and apoptosis30. Most functional lncRNA studies are aimed at understanding the role 
of lncRNAs in cancer progression and metastasis and are based on cancer cell models. The effects of individual 
lncRNAs may thus be difficult to identify among the multiple alterations inherent in malignant cells. Functional 
studies on naturally occurring mutations in nonmalignant cells are rare and may have the potential of dissecting 
individual gene effects in more physiological cell environments. Our findings on cell cycle defects, particularly G2 
progression to mitosis, in fibroblasts from CHH cases with known CHH-causing mutations in RMRP, thus add 
to our limited understanding on the functions of lncRNAs.
Methods
ethics statement. The study protocol was approved by the Institutional Research Ethics Committee of the 
Helsinki University Hospital and University of Helsinki, Finland (76/13/03/03/2011) in accordance with the Helsinki 
Declaration. All study participants were adult and signed an informed consent at recruitment. One participant gave 
a written informed consent for publication of identifying information/images in an online open-access publication.
Study participants. Skin punch biopsies from the left forearm were obtained for fibroblast cultures from five 
patients with CHH and from five healthy controls, all ethnic Finns. All patient-control pairs were matched for sex 
and age, aiming at an age difference of not more than five years. Patients were clinically assessed, and peripheral 
blood DNA was Sanger sequenced for RMRP to confirm the genotype (data not shown)31.
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Fibroblast cultures. The skin biopsy samples were put in sterile fibroblast culture media; Dulbecco’s 
Modified Eagle Medium with 4.5 g/L glucose (DMEM; BioWhittaker, Lonza, Verviers, Belgium), 20% Fetal 
Bovine Serum (FBS Premium; Biowest SAS, Nuaille, France), 50 IU/ml penicillin and 50 µg/ml streptomycin 
(Gibco, Life Technologies Europe, NN Bleiswijk, Netherlands). The skin biopsies were cut into small fragments 
in Phosphate-Buffered Saline (PBS; Gibco, Life Technologies, Carlsbad, CA) on a Petri dish and transferred to 
Falcon tubes containing 3 ml PBS (w/o Mg2+ and Ca2+) and 1,000 U/ml Collagenase Type II: Clostridium histol-
yticum (Gibco). The tubes were incubated at 37 °C for 2 h. Collagenase inactivation was performed by addition of 
3 ml ice cold medium. The tubes were mixed by vortexing and tissue lysates were centrifuged for 10 min, 150 × g 
at 4 °C. The supernatants were removed, the cell pellets were re-suspended in 900 µl media, and transferred to 
T-25 flasks (Corning Life Sciences, New York, NY). 4 ml of media were added to each flask and they were incu-
bated in a 5% CO2 humidified incubator at 37 °C for 1–2 weeks. Fibroblast culture media was changed every 3–4 
days. Once the wells became confluent, the cells were detached using 0.25% trypsin/2.21 mM EDTA (Corning 
Life Sciences, New York, NY) and passed into larger flasks. After 3rd passage the percentage of FBS in media was 
reduced to 15%. The cells were subcultured at regular intervals up to passage six in order to keep adherent cells 
healthy and actively growing. To compare cell growth in cases vs controls, the same number of cells (1.5 × 105) 
was cultured in the 6-well plates (Nunc AS, Thermo Fisher Scientific, Roskilde, Denmark) (three wells for cases 
and three for controls) and the cells were counted at 24, 48 and 72 h.
RNA extraction. RNA from the fibroblasts was isolated using the RNAeasy Mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. RNA integrity was assessed on an Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA) at the Biomedicum Functional Genomics Unit (FuGU, 
Helsinki, Finland). RNA concentrations were measured using a Qubit 2.0 Fluorometer (Thermo Fisher, Carlsbad, 
CA).
RnA sequencing. RNA transcriptome analysis was performed using a modified version of the STRT pro-
tocol32. 10 ng of total RNA were reversely transcribed to cDNA and amplified to make an Illumina-compatible 
sequencing library. Artificial RNA molecules (ERCC RNA Spike-In Mix 1; Life Technologies) were added, ena-
bling normalisation of expression data32. In total, the library was amplified through 25 PCR cycles: unique molec-
ular identifiers (UMIs) were used to reduce amplification biases33.
The library was sequenced on three lanes of Illumina HiSeq2000 (Illumina, San Diego, CA) by using 
single-end 59 bp reads at the Bioinformatics and Expression Analysis (BEA) core facility at Karolinska Institutet, 
Huddinge, Sweden. Sequence data was converted to fastq files using Casava 1.8.2 (Illumina). Demultiplexing by 
the barcodes, exclusion of redundant reads by the UMIs, quality-based filtering, trimming, alignment, quantita-
tion and normalization of expression levels, statistical tests on differential expression, illustration of the expres-
sion levels by heatmap and quality control were performed using the STRTprep pipeline available at https://
github.com/shka/STRTprep/tree/v3dev 32. Differentially expressed genes between cases and controls were those 
with fluctuation p-value < 0.05 (as an assurance of degree of the variation, like as fold-change based thresholding) 
and with differential-expression q-values < 0.05 (as an assurance of difference between the groups; estimated by 
SAMstrt16 from the pipeline), as described in Supplementary data in Krjutskov et al.32.
qRt-pcR validation. Six genes, with robust expression and significantly different expression levels in 
CHH patients and healthy controls by STRT RNA-seq were selected for technical validation by qRT-PCR 
analysis. We included three CHH patients and controls in the qRT-PCR validation and used the same RNA 
Figure 3. Schematic of key CDK complexes and RMRP function during the cell cycle. CHH fibroblasts delay 
in G2 phase. Although effects are pleiotropic and affect many cell cycle regulators, the main Cyclin-CDK 
complexes driving progression through G2 phase show differential regulation in CHH cells. First, mRNA levels 
of CDK2 that stimulates Cyclin A/B-CDK1 activation at the S/G2 border are reduced. Second, CHH cells show 
reduced mRNA levels of direct and indirect regulators of CDK1 activity, as Cdc25C and MAST-L.
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that was used for the initial whole-transcriptome analysis. cDNA was transcribed from 1 μg of total RNA 
using the QuantiTect Reverse Transcription Kit cDNA synthesis kit (Qiagen) according to the manufacturer’s 
protocol. qRT-PCR assays were performed in quintuplicates using the CXF96 Real-Time system (Bio-Rad 
Laboratories, Herkules, CA) and using the TaqMan CDK2, IFITM1, CDKN1A, BCL2L1, ACTB and TBP gene 
expression assays Hs01548894_m1, Hs00705137_s1, Hs00355782_m1, Hs00236329_m1, Hs99999903_m1 and 
Hs00427620_m1, respectively (Applied Biosystems, Thermo Fisher Scientific, Carlsbad, CA). ACTB and TBP 
were used as reference genes for data normalization. Threshold cycle (Ct) values were determined using CFX 
Manager Software (Bio-Rad Laboratories). Relative expression was calculated using the comparative Ct or 
2ΔΔCt method34,35.
Sequencing data Go/KeGG analysis. The DAVID database (v6.8 at https://david.ncifcrf.gov/home.jsp), 
was used to identify enriched GO categories (GO BP_FAT, GO MF_FAT and GO_CC_FAT) and KEGG pathways 
within the set of differentially expressed genes.
Determination of cell cycle delay by EdU incorporation. To label the cells in S phase, cells in passage 
4 or 5 were plated at a density of 3,000 cells per well in a 96-well imaging plate (BD Falcon, Franklin Lakes, NJ) 
and cultured for one day prior to pulse with 1 μM 5-ethynyl-2′-deoxyuridine (EdU; Molecular Probes, Eugene, 
OR) for 1 h. The cells were fixed using 3.7% formaldehyde (Sigma Aldrich, St Louis, MO) for 5 min and permea-
bilised in −20 °C methanol (Sigma Aldrich) for 2 min followed by incubation with DAPI. For the click-chemistry 
reaction, cells were incubated in a solution containing 100 mM Tris (pH 6.8), 1 mM CuS04, 100 mM ascorbic acid 
and azid fluorophore (#A10277, Invitrogen, Carlsbad, CA) for 1 h at room temperature. Images were acquired on 
an ImageXpress imaging system (Molecular Devices, Sunnyvale, CA) using a Nikon Plan Fluor ELWD 20 × 0.45 
NA objective, resulting in 640 × 479 pixel 16-bit images. Image analysis was performed using CellProfiler36. 
Background was subtracted using the CellProfiler inbuilt illumination function with 120-pixel block size. Nuclei 
were segmented based on DAPI intensity using a manually-set threshold and the integrated intensity of DAPI and 
EdU fluorescence was measured.
Determination of duration of mitosis by time-lapse video recording. After 1 day, cells were seeded 
as described above, the plate was placed on the stage of a Leica DMI6000 Imaging system and maintained at 
37 °C with 5% CO2 supply. Differential interference contrast time-lapse video recordings were made at 10-min 
intervals for 29 h using a 20×, 0.4 NA objective. Duration of mitosis was defined as time from cell rounding to 
anaphase.
Data Availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files).
References
 1. Makitie, O. & Kaitila, I. Cartilage-hair hypoplasia–clinical manifestations in 108 Finnish patients. European journal of pediatrics 152, 
211–217 (1993).
 2. Ridanpaa, M. et al. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. 
Cell 104, 195–203 (2001).
 3. Vakkilainen, S., Taskinen, M., Klemetti, P., Pukkala, E. & Mäkitie, O. A 30-year prospective follow-up study reveals risk factors for 
early death in cartilage-hair hypoplasia. Front Immunol 16 July 2019.
 4. Thiel, C. T. & Rauch, A. The molecular basis of the cartilage-hair hypoplasia-anauxetic dysplasia spectrum. Best Pract Res Clin 
Endocrinol Metab 25, 131–142, https://doi.org/10.1016/j.beem.2010.08.004 (2011).
 5. Cai, T., Aulds, J., Gill, T., Cerio, M. & Schmitt, M. E. The Saccharomyces cerevisiae RNase mitochondrial RNA processing is critical 
for cell cycle progression at the end of mitosis. Genetics 161, 1029–1042 (2002).
 6. Thiel, C. T. et al. Severely incapacitating mutations in patients with extreme short stature identify RNA-processing endoribonuclease 
RMRP as an essential cell growth regulator. American journal of human genetics 77, 795–806, https://doi.org/10.1086/497708 
(2005).
 7. Shao, Y. et al. LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric 
cancer. Oncotarget 7, 37812–37824, https://doi.org/10.18632/oncotarget.9336 (2016).
 8. Goldfarb, K. C. & Cech, T. R. Targeted CRISPR disruption reveals a role for RNase MRP RNA in human preribosomal RNA 
processing. Genes & development 31, 59–71, https://doi.org/10.1101/gad.286963.116 (2017).
 9. Pierce, G. F. & Polmar, S. H. Lymphocyte dysfunction in cartilage-hair hypoplasia: evidence for an intrinsic defect in cellular 
proliferation. Journal of immunology 129, 570–575 (1982).
 10. Makitie, O. M., Tapanainen, P. J., Dunkel, L. & Siimes, M. A. Impaired spermatogenesis: an unrecognized feature of cartilage-hair 
hypoplasia. Annals of medicine 33, 201–205 (2001).
 11. Pierce, G. F. & Polmar, S. H. Lymphocyte dysfunction in cartilage hair hypoplasia. II. Evidence for a cell cycle specific defect in T cell 
growth. Clinical and experimental immunology 50, 621–628 (1982).
 12. Juvonen, E. et al. Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and 
history of anaemia. European journal of pediatrics 154, 30–34 (1995).
 13. Yel, L., Aggarwal, S. & Gupta, S. Cartilage-hair hypoplasia syndrome: increased apoptosis of T lymphocytes is associated with altered 
expression of Fas (CD95), FasL (CD95L), IAP, Bax, and Bcl2. Journal of clinical immunology 19, 428–434 (1999).
 14. de la Fuente, M. A. et al. Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with 
cartilage-hair hypoplasia. The Journal of allergy and clinical immunology 128, 139–146, https://doi.org/10.1016/j.jaci.2011.03.042 
(2011).
 15. Islam, S. et al. Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq. Genome research 21, 
1160–1167, https://doi.org/10.1101/gr.110882.110 (2011).
 16. Katayama, S., Tohonen, V., Linnarsson, S. & Kere, J. SAMstrt: statistical test for differential expression in single-cell transcriptome 
with spike-in normalization. Bioinformatics 29, 2943–2945, https://doi.org/10.1093/bioinformatics/btt511 (2013).
 17. Kanehisa, M., Sato, Y., Furumichi, M., Morishima, K. & Tanabe, M. New approach for understanding genome variations in KEGG. 
Nucleic Acids Research 47, D590–D595, https://doi.org/10.1093/nar/gky962 (2019).
8Scientific RepoRtS |         (2019) 9:13758  | https://doi.org/10.1038/s41598-019-50334-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
 18. Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: new perspectives on genomes, pathways, diseases and 
drugs. Nucleic Acids Research 45, D353–D361, https://doi.org/10.1093/nar/gkw1092 (2017).
 19. Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Research 28, 27–30, https://doi.
org/10.1093/nar/28.1.27 (2000).
 20. Ridanpaa, M. et al. Worldwide mutation spectrum in cartilage-hair hypoplasia: ancient founder origin of the major70A–>G 
mutation of the untranslated RMRP. European journal of human genetics: EJHG 10, 439–447, https://doi.org/10.1038/sj.ejhg.5200824 
(2002).
 21. Ridanpaa, M., Jain, P., McKusick, V. A., Francomano, C. A. & Kaitila, I. The major mutation in the RMRP gene causing CHH among 
the Amish is the same as that found in most Finnish cases. American journal of medical genetics. Part C, Seminars in medical genetics 
121c, 81–83, https://doi.org/10.1002/ajmg.c.20006 (2003).
 22. Notarangelo, L. D., Roifman, C. M. & Giliani, S. Cartilage-hair hypoplasia: molecular basis and heterogeneity of the immunological 
phenotype. Current opinion in allergy and clinical immunology 8, 534–539, https://doi.org/10.1097/ACI.0b013e328310fe7d (2008).
 23. Hermanns, P. et al. Consequences of mutations in the non-coding RMRP RNA in cartilage-hair hypoplasia. Human molecular 
genetics 14, 3723–3740, https://doi.org/10.1093/hmg/ddi403 (2005).
 24. Ulici, V., Hoenselaar, K. D., Gillespie, J. R. & Beier, F. The PI3K pathway regulates endochondral bone growth through control of 
hypertrophic chondrocyte differentiation. BMC developmental biology 8, 40, https://doi.org/10.1186/1471-213X-8-40 (2008).
 25. Blachly, J. S. & Baiocchi, R. A. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. British journal of haematology 167, 
19–32, https://doi.org/10.1111/bjh.13065 (2014).
 26. Taskinen, M. et al. Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin 
lymphoma and basal cell carcinoma. American journal of medical genetics. Part A 146A, 2370–2375, https://doi.org/10.1002/
ajmg.a.32478 (2008).
 27. Akopyan, K. et al. Assessing kinetics from fixed cells reveals activation of the mitotic entry network at the S/G2 transition. Molecular 
cell 53, 843–853, https://doi.org/10.1016/j.molcel.2014.01.031 (2014).
 28. Lindqvist, A., Rodriguez-Bravo, V. & Medema, R. H. The decision to enter mitosis: feedback and redundancy in the mitotic entry 
network. The Journal of cell biology 185, 193–202, https://doi.org/10.1083/jcb.200812045 (2009).
 29. Notzold, L. et al. The long non-coding RNA LINC00152 is essential for cell cycle progression through mitosis in HeLa cells. Scientific 
reports 7, 2265, https://doi.org/10.1038/s41598-017-02357-0 (2017).
 30. Yang, Y. et al. Long non-coding RNA GAS5 inhibits cell proliferation, induces G0/G1 arrest and apoptosis, and functions as a 
prognostic marker in colorectal cancer. Oncology letters 13, 3151–3158, https://doi.org/10.3892/ol.2017.5841 (2017).
 31. Kostjukovits, S. et al. Decreased telomere length in children with cartilage-hair hypoplasia. Journal of medical genetics 54, 365–370, 
https://doi.org/10.1136/jmedgenet-2016-104279 (2017).
 32. Krjutskov, K. et al. Single-cell transcriptome analysis of endometrial tissue. Human reproduction 31, 844–853, https://doi.
org/10.1093/humrep/dew008 (2016).
 33. Kivioja, T. et al. Counting absolute numbers of molecules using unique molecular identifiers. Nature methods 9, 72–74, https://doi.
org/10.1038/nmeth.1778 (2011).
 34. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta 
C(T)) method. Methods 25, 402–408, https://doi.org/10.1006/meth.2001.1262 (2001).
 35. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 29, e45, https://doi.
org/10.1093/nar/29.9.e45 (2001).
 36. Kamentsky, L. et al. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis 
software. Bioinformatics 27, 1179–1180, https://doi.org/10.1093/bioinformatics/btr095 (2011).
Acknowledgements
The authors would like to acknowledge laboratory assistants Hanna Hellgren, Maura Kere and Mira Aronen 
for their help in fibroblast culturing, RNA extraction and qRT-PCR validation, and Ingegerd Fransson in 
preparation of the STRT-sequencing library. Leena Saikko is acknowledged for expert assistance in fibroblast 
studies. The authors would like to thank all the patients and healthy volunteers who participated in this study. 
Part of this work was assisted by the BEA Core Facility at Karolinska Institutet, a part of SciLifeLab (https://
www.scilifelab.se/facilities/BEA/). The computations were performed on resources provided by SNIC through 
the Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project 
b2014069. This work was supported by the Swedish Research Council and the Swedish Cancer Society (to 
A.L.); Sigrid Jusélius Foundation, Academy of Finland, Knut and Alice Wallenberg Foundation, Swedish 
Research Council, and Distinguished Professor Award by Karolinska Institutet (to J.K.). J.K. is a recipient 
of The Royal Society Wolfson Research Excellence Award. Academy of Finland, Sigrid Jusélius Foundation, 
Folkhälsan Research Foundation, Novo Nordisk Foundation, Foundation for Pediatric Research, Swedish 
Childhood Cancer Fund (to O.M.).
Author Contributions
O.M. initiated the study. J.K. and O.M. designed the study. S.V. and O.M. recruited study patients. S.V. collected 
clinical data, obtained skin biopsies, and cultured the fibroblasts. M.P. carried out RNA extraction, qRT-PCR 
validation and cell growth studies. T.S. prepared the samples for and organized the sequencing. K.K. performed 
the RNA sequencing. EE performed the RNA transcriptome analysis. S.V., T.S., E.E., S.K., T.Ö., M.V., J.K. 
and O.M. participated in RNA sequencing data interpretation. P.E.K. supervised some functional studies on 
fibroblasts. A.M. and A.L. performed and analyzed cell cycle studies. T.S. coordinated the study. All authors 
contributed to writing of the manuscript and accepted the final manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-50334-6.
Competing Interests: The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
9Scientific RepoRtS |         (2019) 9:13758  | https://doi.org/10.1038/s41598-019-50334-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
